Speakers: Paul Bresge; Eric Daniels, MD and Ethan Rossi, PhD

This session discusses optogenetics, a method of endowing non-photoreceptor cells with light-sensing capabilities. This is the most applicable to late-stage patients.

Speakers: Paul Bresge; Eric Daniels, MD and Ethan Rossi, PhD

This session discusses optogenetics, a method of endowing non-photoreceptor cells with light-sensing capabilities. This is the most applicable to late-stage patients.

Speakers: Katherine Uyhazi, MD, PhD and Srinivasa Sripathi, PhD

Stem cell therapies are based on the premise that we could restore vision if we could replace missing or nonfunctional functional cells, either through transplantation or by inducing existing eye cells to create more photoreceptors. These therapies are likely to be most beneficial for mid- to late-stage patients.

Speakers: Katherine Uyhazi, MD, PhD and Srinivasa Sripathi, PhD

Stem cell therapies are based on the premise that we could restore vision if we could replace missing or nonfunctional functional cells, either through transplantation or by inducing existing eye cells to create more photoreceptors. These therapies are likely to be most beneficial for mid- to late-stage patients.

Speakers: Kenji Fujita, MD and Renee Ryals, PhD

This session will discuss therapies that are gene and/or mutation specific, including gene therapy and genome editing.

Emerging Technologies: Retinal Organoids, RNA Editing, Retinal Prosthetics, and Artificial Intelligence.

Speakers: Robert Bell, PhD; Karl Wahlin, PhD; Hossein Ameri, MD, PhD and Kerry Goetz

This session will discuss hot topics om retinal biology, including retinal organoids, RNA editing, retinal prosthetics, and the use of AI in ophthalmology.

July 12, 2024. Francois Paquet-Durand, PhD, a professor from the University of Tübingen and co-founder of the company Mireca, talks to host Ben Shaberman about the long journey of an emerging, Foundation-funded drug for the treatment of certain forms of retinitis pigmentosa. The episode highlights the challenges that scientists often encounter when developing a drug for a retinal disease, and the persistence and tenacity that are required to keep it moving forward.

FDA-approved in 2021, the tiny implantable capsule provides sustained delivery of treatment, but was recalled in 2022.

For this episode of Eye on the Cure, Michael Telias, PhD, an assistant professor at the University of Rochester in New York, talks with host Ben Shaberman about forthcoming clinical trials to evaluate the FDA-approved drug disulfiram (aka, Antabuse) for improving vision in people with retinitis pigmentosa and other retinal diseases. Disulfiram was originally developed to deter people from abusing alcohol.

Dr. Peter Campochiaro, a clinician-scientist and the Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine, talks to host Ben Shaberman about N-acetylcysteine (NAC), a drug that shows promise for preserving cone vision (central vision and acuity) in people with retinitis pigmentosa. The powerful antioxidant has moved into a 30+ site, Phase 3 clinical trial called NAC Attack.